

[Case Report]

THERAPY-RELATED MYELODYSPLASTIC SYNDROME FOLLOWING CYCLOPHOSPHAMIDE PULSE AND/OR METHOTREXATE THERAPY IN A PATIENT WITH SYSTEMIC LUPUS ERYTHEMATOSUS

HARUYO IWADATE¹⁾, HIROKO KOBAYASHI¹⁾, KIORI YANO¹⁾, HIROSHI WATANABE¹⁾,
KAZUHIKO IKEDA²⁾, KAZUEI OGAWA²⁾ and HIROMASA OHIRA¹⁾

¹⁾Department of Gastroenterology and Rheumatology, Fukushima Medical University School of Medicine, Fukushima 960-1295, Japan, ²⁾Department of Cardiology and Hematology, Fukushima Medical University School of Medicine, Fukushima 960-1295, Japan

(Received December 16, 2009, accepted May 13, 2010)

Abstract : A 27-year-old woman exhibited progressive pancytopenia during cyclophosphamide pulse therapy for lupus nephritis and low-dose methotrexate therapy for severe arthralgia. Bone marrow aspiration revealed highly abnormal cell morphology, indicating therapy-related myelodysplastic syndrome. Pancytopenia and bone marrow cell morphology improved 3 months after discontinuation of cyclophosphamide. It is necessary to promptly examine bone marrow cell morphology and chromosomal aberration in cases with connective tissue diseases complicated by sudden cytopenia during immunosuppressive therapy with chemotherapeutic agents.

Key words : cyclophosphamide, therapy-related myelodysplastic syndrome, systemic lupus erythematosus

INTRODUCTION

Two types of myelodysplastic syndrome (MDS) are known: primary MDS of unknown cause; and therapy-related MDS (T-MDS) that follows administration of antitumor drugs or radiation. T-MDS frequently develops in patients with hematopoietic neoplasms who have received large amounts of antitumor drugs^{1,2)}, although T-MDS has also been reported in cases with connective tissue diseases²⁻⁴⁾. T-MDS is generally resistant to therapy and has poor prognosis^{1,2)}. It is often accompanied by chromosomal aberrations^{1,2)}, and few cases achieve spontaneous remission. Here, we report a rare case of systemic lupus erythematosus that transiently revealed bone marrow cell morphology compatible with MDS during immunosuppressive therapy with cyclophosphamide (CYC) and/or methotrexate (MTX).

CASE REPORT

In 1991, a 16-year old woman exhibited high fever, butterfly rash and photosensitivity, and was diagnosed with systemic lupus erythematosus (SLE) at a local clinic. She was treated with prednisolone (PSL), but continued to have relapses and was referred to our department in 1997 (at age 22 years).

In September 1997, renal biopsy was performed as her urine protein became positive, and she was diagnosed with lupus nephritis (WHO IIIB). She received methyl-PSL pulse therapy followed by CYC pulse therapy (total dose, 3,400 mg) but proteinuria continued. In addition, methotrexate (MTX) at 4 mg/week (total dose, 768 mg) was administered due to high fever and arthralgia, and the amount of PSL was then decreased gradually.

Proteinuria again developed in February 2002. In June, a second renal biopsy was performed, and she was diagnosed with lupus nephritis (WHO IVC). After receiving CYC pulse therapy for 3 months

岩館治代, 小林浩子, 矢野季織, 渡辺浩志, 池田和彦, 小川一英, 大平弘正
Corresponding author: Haruyo Iwadate, M.D. E-mail address: haru-i@fmu.ac.jp
<http://www.jstage.jst.go.jp/browse/fms> <http://fmu.ac.jp/home/lib/F-igaku/>

(monthly dose, 750 mg/month ; total dose, 2,250 mg), proteinuria decreased. However, from the end of August, a high fever of 39°C or more appeared once per week, and anemia progressed simultaneously. The patient was admitted to our department in September 2002 (at age 27 years).

On admission, her palpebral conjunctiva was anemic, and subcutaneous hematoma was observed in the right lower leg. Superficial lymph nodes were not palpable. Laboratory tests revealed an increased erythrocyte sedimentation rate of 41 mm in 1 hour, and a white blood cell count of 9,400/ μ l (11% Band ; 64% Seg ; 5% Ly ; 11% Mo ; 5% Eo ; 2% Myelo ; 1% Meta), decreased hemoglobin of 6.0 g/dl, and platelet count of 11.9×10^4 / μ l. Total protein was 5.4 g/dl, LDH was 330 U/L, Crea was 1.0

mg/dl, and CRP was 1.5 mg/dl. Levels of C3, C4, and CH50 were normal. Anti-DNA antibodies were negative. Urinalysis showed no proteinuria (Table 1). Microbes were not identified on culture of blood, sputum, and urine. Because pancytopenia had progressed (white blood cells, 2,600/ μ l ; hemoglobin, 5.3 g/dl ; platelets 2.9×10^4 / μ l), bone marrow aspiration was performed. She was subsequently diagnosed with MDS and refractory anemia with excess blasts (RAEB-1) (Figures 1A-1C) based on the WHO classification⁵⁾. Slightly hypercellularity of bone marrow was noted in the biopsied sample, but no chromosomal aberrations were present. T-MDS was suspected because bone marrow cell morphology was highly abnormal and had developed during CYC pulse and low-dose

Table 1. Laboratory Findings at Presentation

Peripheral blood		Blood chemistry			
WBC	9,400/ μ l	TP	5.4 g/dl	C ₃	99 mg/dl
Ne	75%	Alb	3.4 g/dl	C ₄	21 mg/dl
Eo	5%	AST	55 IU/l	CRP	1.5 mg/dl
Ba	1%	ALT	28 IU/l	Coombs' test	(-)
Ly	5%	LDH	330 IU/l	ANA	$\times 320$ Sp, CE
Mo	11%	γ -GTP	68 IU/l	a-DNA Ab	5.0 > IU/ml
Myelo	2%	TB	0.6 mg/dl	a-Sm Ab	(-)
Meta	1%	TTT	1.0 mg/dl	a-RNP Ab	93.2 IU/ml
RBC	1.71×10^6 / μ l	ZTT	2.4 mg/dl	a-CL Ab	(-)
Hb	6.0 g/dl	BUN	15 mg/dl	CH50	47.7 U/ml
MCV	107.3 fl	Creatinine	1.0 mg/dl	PAIgG	64.8 ng/10 ⁷
MCH	35.3 pg	UA	10.1 mg/dl	Virological results	
MCHC	32.9%	β 2M	4.29 μ g/dl	EBVEA-IgM (IF)	10 >
Plt	11.9×10^4 / μ l	T-Chol	139 mg/dl	EBVEA-IgG (IF)	(+)40
Ret	11.1% ₀	TG	303 mg/dl	EBNA (IF)	indeterminable
ESR	41 mm/h	Na	142 mEq/l	CMV antigen	0/0
Urinalysis		K	4.1 mEq/l	HSV1 Ab (NT)	(-)
pH 5.5		Cl	107 mEq/l	HSV2 Ab (NT)	(-)
SG 1.018		Fe	114 μ g/dl	Parvovirus B 19 IgM	(-)
Protein (\pm), blood (-)		UIBC	225 μ g/dl	HZVIgM (EIA)	(-)
RBC 1-4/1		Ft	254 ng/dl	HZVIgG (EIA)	(+)
WBC 20-29/1		Vt.B ₁₂	210 pg/ml	Rubella IgM (EIA)	(-)
protein 0.05 g/day		Foric acid	1.8 ng/ml	Rubella IgG (EIA)	(+)
		Serology		Mumps IgM (EIA)	(-)
		IgG	691 mg/dl	Mumps IgG (EIA)	(+)
		IgA	108 mg/dl	HIV-1/2 Ab (CLIA)	(-)
		IgM	28 mg/dl		
		γ -glob	0.6 g/dl		




Fig. 1A.




Fig. 1C.




Fig. 1B.

Fig. 1. Bone marrow aspirate shows abnormal morphologic changes in multilineage blood cells. (A-B) Twenty-four percent of erythroblasts exhibit dysplastic features including multiple nuclei, nuclear fragmentation, and megaloblastic changes. The proportion of myeloblasts was also increased (5.2% in total bone marrow cells; 7.6% in non-erythroid cells), although pseudo-Pelger-Huet anomaly is rare. (C) Morphologic abnormalities such as multiple small nuclei are observed in 10% of megakaryocytes. May-Giemsa stain. Original magnification, $\times 200$ (A,B), $\times 1,000$ (C)




Fig. 2. Clinical course of the present case.
 PSL : prednisolone
 MTX : methotrexate
 CYC : cyclophosphamide

MTX therapy. Administration of CYC and MTX was discontinued, and concentrated red cells were transfused due to severe anemia. Fever declined gradually and pancytopenia improved accordingly. Three months later, bone marrow aspiration revealed improved cell morphology. Clinical course is shown in Figure 2.

DISCUSSION

Drugs, chemicals, viral infection, or radiation can cause acquired bone marrow failure syndromes. In this case, pancytopenia associated with myelodysplasia developed during CYC and pulse therapy for lupus nephritis and low-dose MTX therapy. Bone marrow cell morphology similar to those of RAEB indicated T-MDS, as the patient repeatedly received the alkylating agent CYC.

T-MDS is a myeloid disorder that is seen after chemotherapy or radiotherapy. Approximately half of patients with T-MDS have a history of hematopoietic malignancies, including malignant lymphoma, myeloma and macroglobulinemia^{1,2)}, and the other half have various cancers, although there have also been reports of cases with nonneoplastic disorders, including collagen diseases such as SLE, Behçet's syndrome, and rheumatoid arthritis (RA)^{2-4,6-13)} (Table 2).

Drugs for chemotherapy, particularly alkylating agents such as melpharan and CYC are more likely to induce T-MDS^{14,15)}. Alkylating agents are known to decrease hematopoietic potential for pluripotent stem cells and cause bone marrow hypoplasia. It has been suggested that T-MDS develops based on hematopoietic stem cells injured by chemotherapeutic agents during convalescence from

Table 2. Clinical & pathologic features in patients with connective tissue disease complicated with MDS or AML after chemotherapy

Age	Diagnosis	Medication			Myeloid disorder	Cytogenetics	Outcome
		Type	Cumulative dose, g	Duration, years			
32	SLE	Cytoxan	NA	NA	AML M4Eo	Inv16	remission
23	SLE	AZA	52	0.8	AMML	NA	died
31	SLE	AZA	273	6	SMML	NA	died
24	SLE	AZA	40	0.75	AML	NA	died
67	SLE	CYC	4	1	AML M2	NA	died
32	SLE	CYC/AZA	27/30	0.8/2	AML M4Eo	Inv16, (p13,q22)	remission
44	SLE	CYC/AZA	1.7/37	0.16/2	MDS→AML M2	Monosomy 7	died
41	SLE	CYC/AZA	5.4/89	0.5/7	AML M4	Monosomy 7	remission
40	SLE	AZA	300	6	AML M6	7q(22)-	remission
29	SLE	AZA	55	0.5+0.5	AML	NA	died
50	SLE	CYC/AZA	120/50	4/1.5	AML M5b	NA	died
51	Behçet	CHL	NA	NA	RAEB-T→AML M2	NA	NA
46	Behçet	CHL	NA	NA	AML M2	5q,-3,7,12,20	remission
57	WG	CYC	109	2	MDS-NOS	5q-	died
64	WG	CYC	112.5	3	RAEB-T	7q-	died
75	WG	CYC	120	2	RAEB-T	Monosomy	living
36	TA	CYC	91.2	2	MDS-NOS	7q-	living
72	PM	CHL	6.5	3	RAEB	5q-	died
46	GP	CYC	110	3	MDS-NOS	Monosomy	died

SLE=systemic lupus erythematosus ; WG=Wegener's granulomatosis ;

TA=Takayasu arteritis ; PM=polymyositis ; GP=Goodpasture's syndrome ;

AZA=azathioprine ; CYC=cyclophosphamide ; CHL=chlorambucil ;

AML=acute myeloid leukemia ;

RAEB-T=refractory anemia with excess blasts in transformation ;

MDS-NOS=MDS not otherwise subclassified

AMML=acute myelomonocytic leukemia ; SMML=subacute myelomonocytic leukemia

NA=not available

bone marrow hypoplasia.

Approximately 30% of cases showing T-MDS develop to therapy-induced acute myeloid leukemia (T-AML) each year²⁾, and the condition is often resistant to therapy^{1,2)}. WHO classifications are difficult to apply to T-MDS, as morphological abnormalities in the three blood cell lines are severe. In addition, chromosomal aberrations are seen in 80–90% of cases; abnormal chromosome 5 (5q-) or chromosome 7 (-7) is seen in 50–80%^{1,2)}.

The relative risk of T-MDS and T-AML development by cytostatic agents is 100 times or more that of primary diseases¹⁶⁾; this is presumed to be dependent on total dose¹⁷⁾. Total dose of CYC in this case was 5,650 mg, which did not reach the 20,000 mg considered to influence the relative risk of CYC. Furthermore, bone marrow cell morphology improved 3 months after discontinuation of CYC, and no chromosomal aberrations were seen. For these reasons, a diagnosis of typical T-MDS was not confirmed.

Michels *et al.* suggested that there are three stages of therapy-related panmyelosis: (1) pancytopenia associated with myelodysplastic changes in which the marrow blast count is frequently <5%; (2) frank MDS; and (3) overt AML²⁾. It is possible that this case was in the early stages of T-MDS/T-AML, although long-lasting spontaneous improvement is extremely rare in MDS patients¹⁸⁾.

The patient had been receiving MTX at a dose of 4 mg/week for the treatment of severe arthritis. MTX suppresses DNA synthesis by inhibiting dihydrofolate reductase, and its chromosome-breaking effect leads to damage in bone marrow cells¹⁹⁾. There have been several reports and case series in which hematological malignancies have developed in autoimmune diseases receiving MTX^{4,20–25)}. In particular, there have been case reports of lymphomas and lymphoproliferative disorders (LPDs), developing during MTX therapy for autoimmune diseases, and spontaneously regressing shortly after discontinuation of treatment. Such LPDs are considered to be MTX-associated LPDs, and are recognized by the WHO among the immunodeficiency-associated LPDs²⁶⁾. Although rarely described, MDS have been reported patients with autoimmune diseases after MTX therapy^{27–29)}. Moreover, a relationship between the use of MTX and T-MDS has not been demonstrated^{30–33)}. However, it is possible that combined therapy with MTX and CYC influenced the development of T-MDS in this case.

There have only been two case reports on complicating SLE and MDS^{34,35)}, and in those cases,

MDS developed before SLE, and one showed chromosomal aberrations³⁵⁾. In this case, it was difficult to infer whether MDS was related to SLE.

Some viruses, including HIV, are known to induce hematopoietic failure, such as in MDS. It has been reported that parvovirus B 19 infection elicits transient MDS-like bone marrow findings^{36,37)}, and these cases resulted in spontaneous improvement without treatment. In this case, there was no evidence of viral infection by HIV, parvovirus, cytomegalovirus or EB virus. However, an unknown infection cannot be excluded as a cause of hematopoietic failure, as the patient had high fever before the occurrence of pancytopenia.

Consequently, it is noteworthy that the hematopoietic failure in this case was in the early stages of T-MDS induced by CYC and/or MTX. Alkylating agents are frequently administered to patients with connective tissue diseases, and cytopenia is one of the most common side effects of the drug. It is thus necessary to promptly examine bone marrow cell morphology and chromosomal aberrations in cases with sudden cytopenia during immunosuppressive therapy with chemotherapeutic agents.

REFERENCES

1. Kantarjian HM, Keating MJ, Walters RS, Smith TL, Cork A, McCredie KB, *et al.* Therapy-related leukemia and myelodysplastic syndrome: clinical, cytogenetic, and prognostic features. *J Clin Oncol*, **4**: 1748–1757, 1986.
2. Michels SD, McKenna RW, Arthur DC, Brunning RD. Therapy-related acute myeloid leukemia and myelodysplastic syndrome: a clinical and morphologic study of 65 cases. *Blood*, **65**: 1364–1372, 1985.
3. McCarthy CJ, Sheldon S, Ross CW, McCune WJ. Cytogenetic abnormalities and therapy-related myelodysplastic syndromes in rheumatic disease. *Arthritis Rheum*, **41**: 1493–1496, 1998.
4. Rosenthal NS, Farhi DC. Myelodysplastic syndromes and acute myeloid leukemia in connective tissue disease after single-agent chemotherapy. *Am J Clin Pathol*, **106**: 676–679, 1996.
5. Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. WHO Classification of Tumours. *In*: Pathology & Genetics. A. IARC Press, Lyon, 270–271, 2001.
6. Alexson E, Brandt KD. Acute leukemia after azathioprine treatment of connective tissue disease. *Am J Med Sci*, **273**: 335–340, 1977.
7. Vismans JJ, Briet E, Meijer K, den Ottolander GJ. Azathioprine and subacute myelomonocytic leukemia. *Acta Med Scand*, **207**: 315–319, 1980.
8. Paolozzi FP, Goldberg J. Acute granulocytic leu-

- kemia following systemic lupus erythematosus. *Am J Med Sci*, **290** : 32-35, 1985.
9. Gibbons RB, Westerman E. Acute nonlymphocytic leukemia following short-term, intermittent, intravenous cyclophosphamide treatment of lupus nephritis. *Arthritis Rheum*, **31** : 1552-1554, 1988.
 10. Vasquez S, Kavanaugh AF, Schneider NR, Wacholtz MC, Lipsky PE. Acute nonlymphocytic leukemia after treatment of systemic lupus erythematosus with immunosuppressive agents. *J Rheumatol*, **19** : 1625-1627, 1992.
 11. Kwong YL, Au WY, Liang RHS. Acute myeloid leukemia after azathioprine treatment for autoimmune diseases : association with -7/7q-. *J Rheumatol*, **103** : 94-97, 1998.
 12. Eilertsen GØ, Nossent JC. Erythroleukemia complicating ANA-negative systemic lupus erythematosus. *Scand J Rheumatol*, **36** : 478-489, 2007.
 13. Löfström B, Backlin C, Sundström C, Lindberg EH, Ekblom A, Lundberg IE. Myeloid leukemia in systemic lupus erythematosus—a nested case-control study based on Swedish registers. *Rheumatology*, **48** : 1222-1226, 2009.
 14. Greene MH, Harris EL, Gershenson DM, Malkasian GD Jr, Melton LJ 3rd, Dembo AJ, *et al.* Melphalan may be a more potent leukemogen than cyclophosphamide. *Ann Intern Med*, **105** : 360-367, 1986.
 15. Pedersen-Bjergaard J, Ersboll J, Sorensen HM, Keiding N, Larsen SO, Philip P, *et al.* Risk of acute nonlymphocytic leukemia and preleukemia in patients treated with cyclophosphamide for non-Hodgkin's lymphomas. Comparison with results obtained in patients treated for Hodgkin's disease and ovarian carcinoma with other alkylating agents. *Ann Intern Med*, **103** : 195-200, 1985.
 16. Pedersen-Bjergaard J. Radiotherapy- and chemotherapy-induced myelodysplasia and acute myeloid leukemia. A review. *Leuk Res*, **16** : 61-65, 1992.
 17. Curtis RE, Boice JD Jr, Stovall M, Bernstein L, Greenberg RS, Flannery JT, *et al.* Risk of leukemia after chemotherapy and radiation treatment for breast cancer. *N Engl J Med*, **326** : 1745-1751, 1992.
 18. Breccia M, Latagliata R, Avvisati G, Spadea A, Montefusco E, Aloe Spiriti MA, *et al.* Spontaneous improvement of hematological parameters in 8 patients with myelodysplastic syndromes (MDS). *Leukemia Res*, **21** Supple 1 : S18, 1997.
 19. Jensen MK, Nyfors A. Cytogenetic effects of methotrexate on human cells in vivo : comparison between results obtained by chromosome studies on bone-marrow cells and blood lymphocytes and by the micronucleus test. *Mutat Res*, **64** : 339-343, 1979.
 20. Hazleman B. Incidence of neoplasms in patients with rheumatoid arthritis exposed to different treatment regimens. *Am J Med*, **21** ; **78**(1A) : 39-43, 1985.
 21. Kingsmore SF, Hall BD, Allen NB, Rice JR, Caldwell DS. Association of methotrexate, rheumatoid arthritis and lymphoma : report of 2 cases and literature review. *J Rheumatol*, **19** : 1462-1465, 1992.
 22. Ellman MH, Hurwitz H, Thomas C, Kozloff M. Lymphoma developing in a patient with rheumatoid arthritis taking low dose weekly methotrexate. *J Rheumatol*, 1991 ; **18** : 1741-1743.
 23. Taillan B, Garnier G, Castanet J, Ferrari E, Pesce A, Dujardin P. Lymphoma developing in a patient with rheumatoid arthritis taking methotrexate. *Clin Rheumatol*, 1993 ; **12** : 93-94.
 24. Sliesoraitis S, Khan R, Rothman J. Methotrexate-Induced Hodgkin disease in a patient with systemic lupus erythematosus. *J Am Osteopath Assoc*, 2009 ; **109** : 325-328.
 25. Rizzi R, Curci P, Delia M, Rinaldi E, Chiefa A, Specchia G, Liso V. Spontaneous remission of "methotrexate-associated lymphoproliferative disorders" after discontinuation of immunosuppressive treatment for autoimmune disease. Review of the literature. *Med Oncol*, 2009 ; **26** : 1-9.
 26. Harris NL, Swerdlow SH. Methotrexate-associated lymphoproliferative disorders. *In* : Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health Organization classification of tumors. Pathology and genetics : tumors of haematopoietic and lymphoid tissues. IARC Press, Lyon, France, 270-271, 2001.
 27. Okamoto H, Teramura M, Kamatani N. Myelodysplastic syndrome associated with low-dose methotrexate in rheumatoid arthritis. *Ann Pharmacother*, **38** : 172-173, 2004.
 28. Murphy PT, Fay MJ, Swords RT, Quinn JP, O'Donnell JR. Progression of myelodysplasia during low-dose methotrexate therapy in rheumatoid arthritis. *Ann Pharmacother*, **38** : 1969-1970, 2004.
 29. Thonhofer R, Kriessmayr M, Thonhofer U, Wipfler E, Uitz E, Bahadori B, Eder S. Rheumatoid arthritis patients with-induced myelodysplastic syndrome present with long-term remission after recovery. *Scand J Rheumatol*, **36** : 149-151, 2007.
 30. Hakulinen T, Isomaki H, Knekt P. Rheumatoid arthritis and cancer studies based on linking nationwide registries in Finland. *Am J Med*, **78**(1A) : 29-32, 1985.
 31. Prior P, Symmons DP, Hawkins CF, Scott DL, Brown R. Cancer morbidity in rheumatoid

- arthritis. *Ann Rheum Dis*, **43** : 128-131, 1984.
32. Gridley G, McLaughlin JK, Ekblom A, Klareskog L, Adami HO, Hacker DG, *et al.* Incidence of cancer among patients with rheumatoid arthritis. *J Natl Cancer Inst*, **85** : 307-311, 1993.
 33. Moder KG, Tefferi A, Cohen MD, Menke DM, Luthra HS. Hematologic malignancies and the use of methotrexate in rheumatoid arthritis : a retrospective study. *Am J Med*, **99** : 276-281, 1995.
 34. Ballas SK. Sideroblastic refractory anemia in a patient with systemic lupus erythematosus. *Am J Med Sci*, **265** : 225-231, 1973.
 35. Nakayama S, Nakamura F, Yabe H, Nagai K. Systemic lupus erythematosus in a patient with refractory anemia. *Nippon Ketsueki Gakkai Zasshi*, **52** : 1072-1077, 1989.
 36. Baurmann H, Schwarz TF, Oertel J, Serke S, Roggendorf M, Huhn D. Acute parvovirus B19 infection mimicking myelodysplastic syndrome of the bone marrow. *Ann Hematol*, **64** : 43-45, 1992.
 37. Hiramata T, Kawabata H, Yoshida Y, Okuma M. Reversible pancytopenia accompanied by myelodysplasia. A report of case. *Jpn Arch Intern Med*, **40**, 1-5, 1993.